Zentek (NASDAQ:ZTEK) Stock Price Down 0.1% - Here's What Happened

Key Points

• Zentek Ltd. (NASDAQ:ZTEK) experienced a slight decline in share price, down 0.1% to $0.88, with a trading volume significantly lower than the average.
• Financial metrics indicate a negative return on equity of 55.41% and a negative net margin of 981.17%, while the company reported earnings of ($0.01) per share for the last quarter.
• Zentek is involved in the research and development of graphene and related nanomaterials, creating products such as antimicrobial coatings, surgical masks, and rapid diagnostic tests.

Zentek Ltd. (NASDAQ:ZTEK - Get Free Report)'s share price fell 0.1% during trading on Wednesday . The company traded as low as $0.86 and last traded at $0.88. 56,106 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 824,056 shares. The stock had previously closed at $0.89.

Zentek Stock Down 0.1%

The company has a debt-to-equity ratio of 0.12, a current ratio of 1.62 and a quick ratio of 1.30. The business has a 50 day moving average price of $0.86 and a 200 day moving average price of $1.13. The firm has a market capitalization of $92.57 million, a P/E ratio of -17.68 and a beta of 0.59.

Zentek (NASDAQ:ZTEK - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.01) EPS for the quarter. The business had revenue of $0.04 million during the quarter. Zentek had a negative return on equity of 55.41% and a negative net margin of 981.17%.

Zentek Company Profile

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.